Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
The current Vertex Pharmaceuticals(VRTX) stock price is $450.41, with a market capitalization of 114.32B. The stock trades at a price-to-earnings (P/E) ratio of 26.70.
During the trading session on 2026-05-15, Vertex Pharmaceuticals(VRTX) shares reached a daily high of $456.68 and a low of $447.45. At a current price of $450.41, the stock is +0.7% higher than the low and still -1.4% under the high.
Trading activity shows a volume of 972.03K, compared to an average daily volume of 1.23M.
The stock's 52-week range extends from a low of $362.50 to a high of $507.92.
The stock's 52-week range extends from a low of $362.50 to a high of $507.92.
VRTX News
In early May 2026, Vertex Pharmaceuticals filed a new US$2.87 billion shelf registration for 6,400,000 common shares tied to its employee stock ownership plan a...
Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...
Vertex Pharmaceuticals (VRTX) is back in focus after Germany’s GKV-Spitzenverband agreed to reimburse CASGEVY, widening access to the gene edited therapy and re...
Analyst ratings
76%
of 34 ratingsMore VRTX News
Vertex Pharmaceuticals (NasdaqGS:VRTX) has secured a reimbursement agreement in Germany for its CASGEVY gene therapy for sickle cell disease and beta thalassemi...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.